Agenus Inc. (AGEN) Fair Value 2026

AGEN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-08-27, Agenus Inc. (AGEN) trades at $7.81, versus a $2.85 median fair value across its 2 active models — 63.5% below the current price. QOC: 4.8/10. Value Trap Risk: 36/100 (LOW). 2/13 models active.

Key Facts

Ticker
AGEN
Price
$7.81
Quality Score
4.8/10
Value Trap Risk
36/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.8/10 signals weak fundamentals

Is Agenus Inc. (AGEN) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Agenus Inc. (AGEN) appears overvalued as of : the median of 2 independent fair value estimates is $2.85, 63.5% below the current price of $7.81. Estimates range from $1.59 to $4.11. AGEN scores 4.8/10 on fundamental quality and 36/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. AGEN’s -63.5% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Agenus Inc. Stock in 2026? →

What Fair Value Does Each Model Give AGEN?

2 Intrinsic Value Models vs. Current Price ($7.81)

Core Models (Unlocked)
Model Fair Value Upside
Scenario · High Conviction
 $1.59 -79.7%
Relative · Low Conviction
 $4.11 -47.3%

All Models Active

All 2 models are displayed above.

What Is Agenus Inc. (AGEN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Agenus Inc.'s intrinsic value is estimated at $2.85, suggesting the stock is overvalued at its current price of $7.81. With 2 out of 2 models flagging downside (-63.5% vs price), the market may be pricing in unsustainable growth. Notably, Regime Cross sees the most upside at -47.3% (fair value: $4.11), while First Chicago is the most conservative at -79.7% ($1.59). The spread between these extremes — +32.4% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About AGEN?

2 of 13 models are currently active for AGEN. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for AGEN is $2.85 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does AGEN Rank in Biotechnology?

Among 620 Biotechnology stocks, AGEN ranks #381 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Agenus Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating AGEN should weigh these sector-specific dynamics alongside our model-derived fair values.

Is AGEN a Value Trap?

CirclFi's Value Trap algorithm assigns AGEN a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Agenus Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Agenus Inc.'s fundamental quality profile registers 4.8/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +32.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AGEN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AGEN's 2 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Agenus Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PVLAPalvella Therapeutics, Inc.QOC 4.8RLMDRelmada Therapeutics, Inc.QOC 4.8ANNXAnnexon, Inc.QOC 4.8MBXMBX Biosciences, Inc.QOC 4.8LONALeonaBio, Inc.QOC 4.8ELABPMGC Holdings Inc.QOC 4.8JSPRJasper Therapeutics, Inc.QOC 3.9RCUSArcus Biosciences, Inc.QOC 6.7VRCAVerrica Pharmaceuticals Inc.QOC 5.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PVLA · RLMD · ANNX · MBX · LONA · ELAB · JSPR · RCUS · VRCA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to AGEN?

4 companies across all industries closest to AGEN’s Quality of Company score of 4.8/10.

GITSGlobal Interactive Technologies, Inc.QOC 4.8IFBDInfobird Co., LtdQOC 4.8ICONIcon Energy Corp.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GITS · IFBD · ICON · NVDA

Where Does AGEN Sit in CirclFi's Biotechnology Rankings?

AGEN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Agenus Inc.’s Valuation?

What is Agenus Inc.'s intrinsic value in 2026?

CirclFi puts Agenus Inc. (AGEN)'s intrinsic value at $2.85 — the median of 2 independent model estimates as of 2026-08-27, ranging from $1.59 to $4.11. The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AGEN overvalued or undervalued right now?

At $7.81, 0 of 2 active models suggest AGEN may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $2.85, 63.5% below the current price of $7.81 — a consensus view that AGEN is overvalued. The assessment depends on which methodology best fits Agenus Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.8 mean for AGEN?

Agenus Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on AGEN?

CirclFi analyzes AGEN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is AGEN a value trap in 2026?

Agenus Inc.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Agenus Inc. (AGEN) has a median fair value of $2.85 — 63.5% below the current price of $7.81 — as of 2026-08-27.” Source: circlfi.com/stock/AGEN/ · Methodology
Primary sources for this AGEN valuation
  • Financial statements: Agenus Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001098972) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AGEN as of ; valuations recomputed .